Compare Amphastar Pharmaceuticals Inc (AMPH) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Nutrien Ltd — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Nutrien Ltd trades at $67.28 (market cap $31.60B). The key difference: Nutrien Ltd is far larger — about 36.6× Amphastar Pharmaceuticals Inc's market cap, and Nutrien Ltd pays a 3.32% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | NTR | |
|---|---|---|
Market Cap | $863.95M | $31.60B |
Sector | Health | Basic Materials |
52-Week High | $30.81 | $83.94 |
52-Week Low | $16.87 | $53.64 |
Enterprise Value | $1.26B | $43.40B |
Dividend Yield | — | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Nutrien Ltd. (NTR) trades at $64.42, down 3.51% over 24 hours, with a bearish technical signal. The stock shows mixed earnings, missing Q2 2026 EPS estimates but beating in Q1. Fundamentals include a P/E of 13.04, net income margin of 8.44%, and a dividend of $0.55 per share. Recent news highlights strong potash sales and cost management, though input cost pressures persist.
The outlook is cautiously optimistic, supported by analyst consensus of $76.67 price target and 60.61% buy ratings. Key opportunities include structural gas advantages and agricultural cycle recovery, while risks involve volatile fertilizer demand and margin compression from higher costs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
